Innovator U.S. Equity Ultra Buffer ETF - November (BATS: UNOV)

Latest News for Innovator U.S. Equity Ultra Buffer ETF - November (BATS:UNOV)

Innovator U.S. Equity Ultra Buffer ETF - November

Mizuho analyst Haendel St. Juste maintains VICI Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>) with a Buy and raises the price target from $31 to $32.

News

Price Target

Analyst Ratings

VICI

Mizuho Maintains Buy on VICI Props, Raises Price Target to $32

Guidance

SLVM

Sylvamo Sees Q1 Adj. EBITDA $145M-$160M

Needham analyst Ryan Koontz reiterates Bandwidth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAND#NASDAQ">BAND</a>) with a Hold.

Reiteration

BAND

Needham Reiterates Hold on Bandwidth

Sylvamo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLVM#NYSE">SLVM</a>) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $1.02 by 4.9 percent. The company reported quarterly sales of $905.000 million which beat the analyst consensus estimate of $864.380 million by 4.70 percent. This is a 5.63 percent decrease over sales of $959.000 million the same period last year.

Earnings

Earnings Beats

Sylvamo Q1 2024 Adj EPS $1.07 Beats $1.02 Estimate, Sales $905M Beat $864.380M Estimate

Mizuho analyst Vikram Malhorta maintains Gaming and Leisure Props (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>) with a Neutral and lowers the price target from $47 to $46.

GLPI

Mizuho Maintains Neutral on Gaming and Leisure Props, Lowers Price Target to $46

For the full year 2024, we expect:
<ul>
<li>Total revenue of&nbsp;$760&nbsp;to&nbsp;$775 million.</li>
<li>Adjusted EBITDA margin of&nbsp;36%&nbsp;to&nbsp;38%.</li>
<li>Adjusted free cash flow margin in the range of&nbsp;19%&nbsp;to&nbsp;21%&nbsp;of revenue.</li>
<li>Non-GAAP diluted net income per share of&nbsp;$1.60&nbsp;to&nbsp;$1.67.</li>
<li>Fully diluted weighted average shares outstanding of approximately 102 to 103 million shares.</li>
</ul>

DOCN

DigitalOcean Holdings Expects FY24 Revenue of $760M-$775M (Prior $755M-$775M) Vs $766.36M Est, Adj EPS of $1.60-$1.67 Vs $1.64 Est

Needham analyst Ryan Koontz maintains Kaltura (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTR#NASDAQ">KLTR</a>) with a Buy and lowers the price target from $5 to $3.

KLTR

Needham Maintains Buy on Kaltura, Lowers Price Target to $3

Biotech

Large Cap

Health Care

General

MRNA

Moderna Says That FDA, Due To Administrative Constraints, Does Not Expect To Complete Its Review Of mRNA-1345, Respiratory Syncytial Virus Vaccine, By May 12, The FDA Has Informed Moderna That It Is Working To Conclude The Review By The End Of May

Ubiquiti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) reported quarterly earnings of $1.28 per share which missed the analyst consensus estimate of $1.56 by 17.95 percent. This is a 22.42 percent decrease over earnings of $1.65 per share from the same period last year. The company reported quarterly sales of $493.00 million which beat the analyst consensus estimate of $479.64 million by 2.78 percent. This is a 7.69 percent increase over sales of $457.77 million the same period last year.

Earnings Misses

Ubiquiti Q3 Adj $1.28 Misses $1.56 Estimate, Sales $493.00M Beat $479.64M Estimate

Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) reported quarterly losses of $(2.39) per share which missed the analyst consensus estimate of $(2.23) by 7.17 percent.

Instil Bio Q1 2024 GAAP EPS $(2.39) Misses $(2.23) Estimate

i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) reported quarterly earnings of $0.34 per share which missed the analyst consensus estimate of $0.38 by 10.53 percent. This is a 10.53 percent decrease over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $94.542 million which missed the analyst consensus estimate of $97.895 million by 3.42 percent. This is a 0.71 percent increase over sales of $93.872 million the same period last year.

IIIV

i3 Verticals Q2 2024 Adj EPS $0.34 Misses $0.38 Estimate, Sales $94.542M Miss $97.895M Estimate

Mizuho analyst Vikram Malhorta maintains Realty Income (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) with a Buy and raises the price target from $56 to $59.

Mizuho Maintains Buy on Realty Income, Raises Price Target to $59

Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) reported quarterly earnings of C$0.92 per share which beat the analyst consensus estimate of C$0.82 by 12.2 percent. This is a 8.24 percent increase over earnings of C$0.85 per share from the same period last year.

Enbridge Q1 2024 Adj EPS C$0.92 Beats C$0.82 Estimate

Wedbush analyst Nick Setyan maintains Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Outperform and lowers the price target from $76 to $65.

PZZA

Wedbush Maintains Outperform on Papa John's International, Lowers Price Target to $65

FDA Has Has Informed Moderna That Due To Administrative Constraints, It Will Not Complete Its Review Of MRNA-1345 By The PDUFA Date Of May 12

Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $0.04 by 2103.25 percent. The company reported quarterly sales of $152.177 million which beat the analyst consensus estimate of $113.850 million by 33.67 percent. This is a 12.16 percent increase over sales of $135.680 million the same period last year.

TSAT

Telesat Q1 2024 GAAP EPS $(0.80) Misses $0.04 Estimate, Sales $152.177M Beat $113.850M Estimate

Mizuho analyst Vikram Malhorta maintains Essential Props Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>) with a Buy and raises the price target from $26 to $29.

EPRT

Mizuho Maintains Buy on Essential Props Realty, Raises Price Target to $29

Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 19.44 percent increase over losses of $(0.36) per share from the same period last year.

HUMA

Humacyte Q1 EPS $(0.29) Misses $(0.23) Estimate, Exits Quarter With Cash & Equivalents Worth $115.5M

Financial&nbsp;Outlook:
Based on information available as of May 10, 2024, for the&nbsp;second quarter&nbsp;of 2024 we expect:
<ul>
<li>Total revenue of&nbsp;$188&nbsp;to&nbsp;$189 million.</li>
<li>Adjusted EBITDA margin of&nbsp;37%&nbsp;to&nbsp;38%.</li>
<li>Non-GAAP diluted net income per share of&nbsp;$0.38&nbsp;to&nbsp;$0.40.</li>
<li>Fully diluted weighted average shares outstanding of approximately 102 to 103 million shares.</li>
</ul>
For the full year 2024, we expect:
<ul>
<li>Total revenue of&nbsp;$760&nbsp;to&nbsp;$775 million.</li>
<li>Adjusted EBITDA margin of&nbsp;36%&nbsp;to&nbsp;38%.</li>
<li>Adjusted free cash flow margin in the range of&nbsp;19%&nbsp;to&nbsp;21%&nbsp;of revenue.</li>
<li>Non-GAAP diluted net income per share of&nbsp;$1.60&nbsp;to&nbsp;$1.67.</li>
<li>Fully diluted weighted average shares outstanding of approximately 102 to 103 million shares.</li>
</ul>